Results 221 to 230 of about 5,770,101 (353)

Pipe dream to pipeline: Journey of cancer vaccines and the road ahead. [PDF]

Cell Rep Med
Onkar S, Bozkus CC, Saxena M, Bhardwaj N.   +3 more
europepmc   +1 more source

Current evidence and insights on single vs. double dose of basiliximab in adult solid organ transplant recipients: A systematic review

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim The aim of this systematic review was to assess all available clinical data regarding the use of a single dose of basiliximab in solid organ transplantation compared to the standard double dosage, with particular interest in efficacy, safety and cost‐savings.
Alessio Provenzani, Braidon A. Lape, Anneliese M. Harp, Victoria Weisbrod, Lavinia Piazza   +4 more
wiley   +1 more source

Personalized Cancer Vaccines: Current Advances and Emerging Horizons. [PDF]

Vaccines (Basel)
Lu L, Lu X, Luo W.
europepmc   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

Breast cancer vaccines: from immune promise to the prospect of eradication. [PDF]

Ann Med Surg (Lond)
Imtiaz A, Abdullah T, Hassan S, Fatima M.   +3 more
europepmc   +1 more source

Prospects and Challenges of Lung Cancer Vaccines. [PDF]

Vaccines (Basel)
Lin Z, Chen Z, Pei L, Chen Y, Ding Z.
europepmc   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Lung cancer vaccines to enhance immune checkpoint inhibitor therapy: evidence and future perspectives. [PDF]

J Hematol Oncol
Tang Z, Zha L, Liang R, Li T.
europepmc   +1 more source

Increasing the reporting of adverse drug reaction‐related hospitalizations using an ICD‐10‐based identification workflow: A multicentre study from Switzerland

British Journal of Clinical Pharmacology, EarlyView.
Background Reporting adverse drug reactions (ADRs) is essential for drug safety. In Switzerland, healthcare professionals are legally required to report serious and unlabelled ADRs, yet under‐reporting remains widespread. We tested a novel method to increase reporting of ADR‐related hospitalizations.
Georgia Anita Weber, Sophie‐Charlotte Bartel, Michael Boch, Christoph Rosen, Michael Bodmer, Balthasar Luzius Hug, Thomas Stammschulte, Patrick E. Beeler   +7 more
wiley   +1 more source

Personalized and HPV cancer vaccines in head and neck squamous cell carcinoma: from concept to clinical implementation. [PDF]

Transl Oncol
Filippini DM, Le Tourneau C.
europepmc   +1 more source